Selected article for: "causative agent and disease progression"

Author: Tay, Matthew Zirui; Poh, Chek Meng; Rénia, Laurent; MacAry, Paul A.; Ng, Lisa F. P.
Title: The trinity of COVID-19: immunity, inflammation and intervention
  • Cord-id: rcdoewwv
  • Document date: 2020_4_28
  • ID: rcdoewwv
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Alongside investigations into the virology of SARS-CoV-2, understanding the fundamental physiological and immunological processes underlying the clinical manifestations of COVID-19 is vital for the identification and rational design of effective therapies. Here, we provide an overview of the pathophysiology of SARS-CoV-2 infection. We describe the inter
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Alongside investigations into the virology of SARS-CoV-2, understanding the fundamental physiological and immunological processes underlying the clinical manifestations of COVID-19 is vital for the identification and rational design of effective therapies. Here, we provide an overview of the pathophysiology of SARS-CoV-2 infection. We describe the interaction of SARS-CoV-2 with the immune system and the subsequent contribution of dysfunctional immune responses to disease progression. From nascent reports describing SARS-CoV-2, we make inferences on the basis of the parallel pathophysiological and immunological features of the other human coronaviruses targeting the lower respiratory tract — severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Finally, we highlight the implications of these approaches for potential therapeutic interventions that target viral infection and/or immunoregulation.

    Search related documents:
    Co phrase search for related documents
    • aberrant inflammatory response and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6
    • aberrant inflammatory response and adaptive immune response: 1
    • active infection and acute lung injury: 1, 2, 3, 4, 5
    • active infection and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active infection and adaptive immune response: 1, 2, 3, 4, 5
    • active replication and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active replication and adaptive immune response: 1, 2
    • active replication and local immune response: 1
    • acute lung injury and adaptive immune response: 1, 2, 3, 4, 5
    • acute lung injury and ade antibody dependent enhancement: 1
    • acute lung injury and adjunctive therapy: 1, 2, 3
    • acute lung injury and local damage: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and ade antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute sars cov respiratory syndrome coronavirus and local damage: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and local immune response: 1, 2, 3, 4, 5, 6
    • adaptive immune response and ade antibody dependent enhancement: 1
    • adaptive immune response and local immune response: 1, 2, 3